Abliva’s IND for clinical development of KL1333 approved by FDA
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the US Foo ...